Citius Pharmaceuticals

Citius Pharmaceuticals (NASDAQ: CTXR) is a late-stage biopharmaceutical company headquartered in Cranford, New Jersey, focused on the development and commercialization of first-in-class critical care products spanning oncology, adjunct cancer care, anti-infectives, and stem cell therapy. Its majority-owned subsidiary, Citius Oncology (NASDAQ: CTOR), commercializes LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma. On August 5, 2026, Citius Oncology reported that new institutional accounts ordering LYMPHIR rose 78% quarter over quarter with near-universal payer coverage, an update that drove both CTXR (+25.45%) and CTOR (+18.94%) sharply higher.